Drug profile · INN
mirikizumab-mrkz
OMVOH
mirikizumab-mrkz (OMVOH) is a interleukin-23 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — mirikizumab-mrkz
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
mirikizumab-mrkz (OMVOH) is a interleukin-23 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-23 inhibitor
Primary target: Interleukin-23
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is mirikizumab-mrkz?
mirikizumab-mrkz (OMVOH) is a interleukin-23 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for mirikizumab-mrkz?
OMVOH is a marketed brand name for mirikizumab-mrkz. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mirikizumab-mrkz?
mirikizumab-mrkz has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.